// App-Quantinova.ai

P096 : Effect Of Ozanimod On Circulating Leukocyte Subtypes In Patients With Relapsing Multiple Sclerosis: Results From A Phase 1 Study

Researchers

Presenter

  • S. Harris

Principal Investigators

  • J. Q. Tran

  • H. Southworth

  • C. M. Spencer

  • B. A. Cree

  • S. S. Zamvil

Medical Centers

  • Celgene Corporation, Summit, NJ

  • Data Clarity Consulting Ltd., Stockport, United Kingdom

  • Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, USA San Francisco CA United States

Locations

  • United States

  • United Kingdom

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

Biomarkers

  • N/A

Drug/Treatment

  • Ozanimod

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Dose Escalation

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved